ArticleJournal of the American Heart Association2020
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Comparative Effectiveness and Safety of Various Anticoagulation Regimens for Portal Venous Thrombosis in Cirrhosis: A Systematic Review and Network Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.Journal of the American Heart Association · 2026Trial
- Long-term incidence of post-thrombotic syndrome in carriers of inherited thrombophilia treated with direct oral anticoagulants versus vitamin K antagonists.Journal of thrombosis and thrombolysis · 2026Article
- Risk and management of congenital thrombophilia in transgender individuals undergoing gender-affirming hormone therapy.International journal of transgender health · 2026Article
- Functional Antithrombin (AT) Deficiency Presenting as Multiterritorial Splanchnic Vein Thrombosis: A Case Report.Case reports in hematology · 2026Article
- Article
- Anticoagulation Failure in Stroke: Causes, Risk Factors, and Treatment.Journal of stroke · 2025Review
- The novel SERPINC1 missense mutation c.1148 T > A (p.L383H) causes hereditary antithrombin deficiency and thromboembolism in a Chinese family: a case report.Journal of medical case reports · 2025Article
- Review
- Efficacy and safety of direct oral anticoagulants in patients with venous thrombosis and inherited thrombophilia.International journal of medical sciences · 2025Article
- Multisystem embolism in hereditary protein C deficiency with patent foramen ovale: a case report.Frontiers in cardiovascular medicine · 2025Article
- Article
- Efficacy and Safety of Direct Oral Anticoagulants After Mechanical Thrombectomy in Venous Thromboembolism: A Comparative Study of 55 Patients.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Prothrombotic Rebound After Discontinuation of Direct Oral Anticoagulants Therapy: A Systematic Review.Journal of clinical medicine · 2024Review
- Secondary prophylaxis of venous thromboembolism (VTE) with low dose apixaban or rivaroxaban in major-thrombophilia carriers.Annals of hematology · 2024Article
- Proteome and Metabolome Profiling of Anticoagulant Disorders Induced by Familial Protein S Deficiency.Journal of proteome research · 2024Article
- Ramadan intermittent fasting is associated with improved anticoagulant activity among healthy people: a case-control study.Scientific reports · 2024Article
- Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis.Scientific reports · 2024Article
- Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry.Journal of thrombosis and thrombolysis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background In this prospective cohort study, we aimed to evaluate the efficacy and safety of direct oral anticoagulants (DOACs) versus heparin/vitamin K antagonists for the treatment of venous thromboembolism (VTE) in patients with inherited thrombophilia. Methods and Results We enrolled consecutive patients with acute VTE and inherited thrombophilia treated with DOACs (cases) or heparin/vitamin K antagonists (controls), matched for age, sex, ethnicity, and thrombophilia type. End points were VTE recurrence and bleeding complications; residual vein thrombosis and post-thrombotic syndrome; VTE recurrence after anticoagulant discontinuation. Two hundred fifty-five cases (age 52.4±17.3 years, Female 44.3%, severe thrombophilia 33.1%) and 322 controls (age 49.7±18.1 years, Female 50.3%, severe thrombophilia 35.1%) were included. The cumulative incidence of VTE recurrence during anticoagulation was 1.09% in cases versus 1.83%, adjusted hazard ratio (HR) 0.67 (95% CI, 0.16-2.77). The cumulative incidence of bleeding was 10.2% in cases versus 4.97%, HR 2.24 (95% CI 1.10-4.58). No major bleedings occurred in cases (versus 3 in controls). No significant differences regarding residual vein thrombosis and post-thrombotic syndrome. After anticoagulant discontinuation, DOACs yielded a significantly lower 2-year VTE recurrence risk versus traditional anticoagulants (HR, 0.61 [95% CI, 0.47-0.82]). Conclusions DOACs and heparin/vitamin K antagonists showed a similar efficacy in treating VTE in patients with thrombophilia. Although major bleeding episodes were recorded solely with heparin/vitamin K antagonists, we noted an overall increased bleeding rate with DOACs. The use of DOACs was associated with a lower 2-year risk of VTE recurrence after anticoagulant discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.